Integer Holdings Corporation $ITGR Holdings Boosted by Raymond James Financial Inc.

Key Points

• Raymond James Financial Inc. increased its stake in Integer Holdings Corporation by 6.9%, owning approximately $36.25 million worth of shares after purchasing an additional 19,839 shares in the first quarter.
• Integer's stock price is showing positive momentum, up 3.6%, with a 52-week high of $146.36 and a current trading price of $110.65.
• Several hedge funds have recently modified their positions in Integer, with 99.29% of the stock now owned by institutional investors, indicating strong institutional interest in the company.

Raymond James Financial Inc. grew its stake in shares of Integer Holdings Corporation (NYSE:ITGR - Free Report) by 6.9% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 307,141 shares of the medical equipment provider's stock after buying an additional 19,839 shares during the quarter. Raymond James Financial Inc. owned 0.88% of Integer worth $36,245,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its position in shares of Integer by 14.7% in the 1st quarter. Russell Investments Group Ltd. now owns 6,749 shares of the medical equipment provider's stock worth $796,000 after purchasing an additional 863 shares during the period. Public Sector Pension Investment Board increased its position in shares of Integer by 27.4% during the 1st quarter. Public Sector Pension Investment Board now owns 106,382 shares of the medical equipment provider's stock valued at $12,554,000 after purchasing an additional 22,847 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Integer during the 1st quarter valued at about $17,634,000. Aigen Investment Management LP purchased a new stake in shares of Integer during the 1st quarter valued at about $572,000. Finally, Entropy Technologies LP bought a new position in shares of Integer during the 1st quarter valued at approximately $719,000. Hedge funds and other institutional investors own 99.29% of the company's stock.

Insider Buying and Selling at Integer

In other news, Director Donald J. Spence sold 14,739 shares of the company's stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $120.38, for a total value of $1,774,280.82. Following the sale, the director directly owned 18,781 shares in the company, valued at $2,260,856.78. This represents a 43.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Martin C. Maxwell sold 8,720 shares of the company's stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $120.56, for a total value of $1,051,283.20. Following the completion of the transaction, the director owned 22,170 shares of the company's stock, valued at $2,672,815.20. The trade was a 28.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on ITGR. Raymond James Financial lowered their price target on Integer from $150.00 to $143.00 and set an "outperform" rating on the stock in a report on Friday, July 25th. Wells Fargo & Company lowered their target price on Integer from $152.00 to $132.00 and set an "overweight" rating for the company in a report on Friday, July 25th. Truist Financial lowered their target price on Integer from $145.00 to $137.00 and set a "buy" rating for the company in a report on Friday, July 25th. Citigroup raised Integer from a "hold" rating to a "strong-buy" rating and increased their target price for the company from $133.00 to $140.00 in a research report on Thursday, May 22nd. Finally, Wall Street Zen raised Integer from a "sell" rating to a "hold" rating in a research report on Monday, May 19th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $140.25.

Integer Stock Down 0.1%

Integer stock traded down $0.13 during trading on Tuesday, reaching $108.66. The stock had a trading volume of 223,079 shares, compared to its average volume of 340,849. The company has a quick ratio of 2.18, a current ratio of 3.41 and a debt-to-equity ratio of 0.72. Integer Holdings Corporation has a 52-week low of $104.93 and a 52-week high of $146.36. The business has a 50 day moving average price of $113.36 and a 200 day moving average price of $118.60. The stock has a market cap of $3.81 billion, a PE ratio of 47.87, a P/E/G ratio of 0.86 and a beta of 1.02.

Integer (NYSE:ITGR - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.02). Integer had a return on equity of 12.27% and a net margin of 4.61%.The company had revenue of $476.00 million for the quarter, compared to analyst estimates of $464.37 million. During the same period in the previous year, the business posted $1.30 EPS. The firm's revenue for the quarter was up 11.4% compared to the same quarter last year. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. On average, analysts predict that Integer Holdings Corporation will post 6.01 EPS for the current year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.